In today’s era, breakthroughs in pharmaceuticals often depend on mastering complex chemical synthesis. Tianming Pharmaceutical is proud to announce a milestone achievement: the successful commercialization of orforglipron intermediates.
After years of relentless research, strategic problem-solving, and cross-functional collaboration, our team overcame the technical and logistical obstacles that once hindered the global production of this critical compound.
Today, we share our journey and capabilities with the global scientific community and industry partners.
Orforglipron is a next-generation therapeutic drug gaining increasing attention in metabolic disorder research, whose synthesis relies on a complex network of intermediates.
These intermediates typically feature unstable molecular structures and stringent production conditions, posing long-standing challenges for manufacturers. A minor error in temperature control, catalyst selection, or purification protocols could render an entire batch of the process ineffective, making scalable production a long-sought-after goal for chemists worldwide.
At Tianming Pharmaceuticals, we recognized early on that mastering the intermediates for Gliclazide requires not only chemical expertise but also redefining the possibilities of API production.
Our R&D team first analyzed the molecular structure of Gliclazide, identifying three core intermediates as key pathways.
Catalyst Optimization: Traditional palladium catalysts were inefficient for synthesizing intermediates. After multiple iterations, our team pioneered a catalyst system that reduced reaction time by 60% while maintaining a 99% ee value (enantiomeric excess).
Stability Breakthrough: We designed a proprietary solvent system to inhibit hydrolysis, significantly reducing degradation rates during post-processing.
Process Enhancement: By integrating continuous flow chemistry technology, we increased yield from 68% (batch) to 89% at a 10x scale.
Every kilogram of orforglipron intermediates produced at our cGMP-certified facility undergoes the following processes:
Heavy metal screening via ICP-MS
Residual solvent testing in accordance with ICH Q3C guidelines
Below is our commercially validated product portfolio to help accelerate your drug development:
Name | Chemical Information | Cas.NO |
1-(cyanomethyl)-5-[(4S)-2,2-dimethyloxan-4-yl]-N-methyl-N-phenylin-dole-2-carboxamid | Chemical Formula: Molecular Weight: 401.51 | 2212021-80-0 |
5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-1-((1S,2S)-1-((Z)-N’-hydroxycarbamimidoyl)-2-methylcyclopropyl)-N-methyl-N-phenyl-1H-indole-2-carboxamide | Chemical Formula: C28H34N4O3 Molecular Weight: 474.61 | 3047556-95-3 |
5-[(4S)-2,2-dimethyloxan-4-yl]-N-methyl-1-[(1 S,2S)-2-methyl-1-(5-oxo-4H-1,2,4-oxadiazol-3-yl)cyclopropyl]-N-phenylindole-2-carboxamide | Chemical Formula: Molecular Weight: 500.60 | 2212021-82-2 |
5-[(S)-2,2-Dimethyltetrahydro-2H-pyran-4-yl]-1-[(1S,2S)-2-methyl-1-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)cyclopropyl]-1H-indole-2-carboxylic Acid | Chemical Formula: C22H25N3O5 Molecular Weight: 411.46 | 2212021-83-3 |
tert-butyl (S)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-3-(2-oxo-2,3-dihydro-1H-imida-zol-1-yl)-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylat | Chemical Formula: Molecular Weight: 441.51 | 2212021-61-7 |
5-bromo-4-fluoro-1-methyl-1H-indazole | Chemical Formula: C8H6BrFN2 Molecular Weight: 229.05 | 1784678-61-0 |
tert-butyl (4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carboxylate | Chemical Formula: C31H33F2N7O3 Molecular Weight: 589.65 | 2212022-55-2 |
(S)-1-(4-fluoro-2-methyl-2H-indazol-5-yl)-3-(2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)-1H-imidazol-2(3H)-one | Chemical Formula: C26H25F2N7O Molecular Weight: 489.53 | 2212022-56-3 |
Orforglipron | Chemical Formula: C48H48F2N10O5 Molecular Weight: 882.97 | 2212020-52-3 |
Complete specifications and production license (COA) are available upon request.
Tianming Pharmaceutical is now inviting pharmaceutical companies, contract research organizations (CROs), and research institutions to utilize our orforglipron intermediates for the following purposes:
We invite all interested parties to contact us for more information about orforglipron intermediates. Whether you are a pharmaceutical company in need of these key compounds or a researcher seeking collaboration, we are eager to connect with you and explore potential partnerships.
Contact us immediately Email: sunqian0123@gamil.com
Regulatory differences between API and intermediate manufacturing under ICH Q7, FDA, EMA, and NMPA. GMP boundaries, DMF filing, starting material justification.
Finerenone drug class: third‑generation non‑steroidal MRA. Compare selectivity, potency, half‑life, and safety vs spironolactone/eplerenone. FDA‑approved for CKD+T2D and HF with LVEF ≥40%.
Finerenone mechanism of action: a non‑steroidal mineralocorticoid receptor antagonist with high MR selectivity, balanced cardiorenal distribution, no active metabolites, and lower hyperkalemia risk vs steroidal MRAs.
Leading provider of high-quality APIs and intermediates. Contact us for innovative solutions and expert support.